Mitozolomide
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.079.921 |
Chemical and physical data | |
Formula | C7H7ClN6O2 |
Molar mass | 242.62 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]
References
- ^ Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther. 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631. S2CID 2597751.
- ^ Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer. 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719. PMID 1739631.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Abandoned drugs
- Imidazotetrazines
- Carboxamides
- Organochlorides
- All stub articles
- Antineoplastic and immunomodulating drug stubs